KR20240007152A - Nlrp3 억제제 - Google Patents
Nlrp3 억제제 Download PDFInfo
- Publication number
- KR20240007152A KR20240007152A KR1020237038678A KR20237038678A KR20240007152A KR 20240007152 A KR20240007152 A KR 20240007152A KR 1020237038678 A KR1020237038678 A KR 1020237038678A KR 20237038678 A KR20237038678 A KR 20237038678A KR 20240007152 A KR20240007152 A KR 20240007152A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- phenyl
- amino
- hydroxy
- piperidyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21173452.0 | 2021-05-12 | ||
| EP21173452 | 2021-05-12 | ||
| EP21209447 | 2021-11-22 | ||
| EP21209447.8 | 2021-11-22 | ||
| EP21215859.6 | 2021-12-20 | ||
| EP21215859 | 2021-12-20 | ||
| PCT/EP2022/062525 WO2022238347A1 (en) | 2021-05-12 | 2022-05-10 | Nlrp3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240007152A true KR20240007152A (ko) | 2024-01-16 |
Family
ID=81941106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237038678A Pending KR20240007152A (ko) | 2021-05-12 | 2022-05-10 | Nlrp3 억제제 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240208928A1 (https=) |
| EP (2) | EP4337652B1 (https=) |
| JP (1) | JP2024517917A (https=) |
| KR (1) | KR20240007152A (https=) |
| AR (1) | AR125818A1 (https=) |
| AU (1) | AU2022275300A1 (https=) |
| BR (1) | BR112023023527A2 (https=) |
| CA (1) | CA3214626A1 (https=) |
| CL (1) | CL2023003312A1 (https=) |
| CO (1) | CO2023016204A2 (https=) |
| CR (1) | CR20230529A (https=) |
| DK (1) | DK4337652T3 (https=) |
| ES (1) | ES3031704T3 (https=) |
| FI (1) | FI4337652T3 (https=) |
| HR (1) | HRP20250632T1 (https=) |
| HU (1) | HUE071498T2 (https=) |
| IL (1) | IL307188A (https=) |
| LT (1) | LT4337652T (https=) |
| MA (1) | MA64323B1 (https=) |
| MX (1) | MX2023012907A (https=) |
| PE (1) | PE20240126A1 (https=) |
| PL (1) | PL4337652T3 (https=) |
| RS (1) | RS66893B1 (https=) |
| SI (1) | SI4337652T1 (https=) |
| WO (1) | WO2022238347A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| IL314025A (en) * | 2022-01-07 | 2024-08-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| AU2023371859A1 (en) * | 2022-11-04 | 2025-06-12 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| PE20251845A1 (es) * | 2022-12-07 | 2025-07-17 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibicion de nlrp3 |
| WO2024158941A2 (en) * | 2023-01-27 | 2024-08-02 | Mwyngil Therapeutics, Inc. | Inhibitors of nlrp3 |
| JP2026511027A (ja) * | 2023-03-20 | 2026-04-10 | インシリコ メディスン アイピー リミティド | Ｎｌｒｐ３インフラマソーム阻害剤及びその使用 |
| WO2024193699A1 (zh) | 2023-03-23 | 2024-09-26 | 成都赜灵生物医药科技有限公司 | 三嗪类化合物及其用途 |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| IL324489A (en) | 2023-06-29 | 2026-01-01 | Hoffmann La Roche | Triazine derivatives as NLRP3 inhibitors |
| CN121586712A (zh) | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| WO2025059069A1 (en) * | 2023-09-12 | 2025-03-20 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653316B1 (en) * | 1999-05-19 | 2003-11-25 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade |
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
-
2022
- 2022-05-10 AR ARP220101225A patent/AR125818A1/es unknown
- 2022-05-10 PL PL22728228.2T patent/PL4337652T3/pl unknown
- 2022-05-10 CA CA3214626A patent/CA3214626A1/en active Pending
- 2022-05-10 HU HUE22728228A patent/HUE071498T2/hu unknown
- 2022-05-10 EP EP22728228.2A patent/EP4337652B1/en active Active
- 2022-05-10 LT LTEPPCT/EP2022/062525T patent/LT4337652T/lt unknown
- 2022-05-10 JP JP2023569634A patent/JP2024517917A/ja active Pending
- 2022-05-10 HR HRP20250632TT patent/HRP20250632T1/hr unknown
- 2022-05-10 MX MX2023012907A patent/MX2023012907A/es unknown
- 2022-05-10 DK DK22728228.2T patent/DK4337652T3/da active
- 2022-05-10 MA MA64323A patent/MA64323B1/fr unknown
- 2022-05-10 RS RS20250561A patent/RS66893B1/sr unknown
- 2022-05-10 IL IL307188A patent/IL307188A/en unknown
- 2022-05-10 PE PE2023002971A patent/PE20240126A1/es unknown
- 2022-05-10 FI FIEP22728228.2T patent/FI4337652T3/fi active
- 2022-05-10 SI SI202230138T patent/SI4337652T1/sl unknown
- 2022-05-10 AU AU2022275300A patent/AU2022275300A1/en active Pending
- 2022-05-10 WO PCT/EP2022/062525 patent/WO2022238347A1/en not_active Ceased
- 2022-05-10 BR BR112023023527A patent/BR112023023527A2/pt unknown
- 2022-05-10 KR KR1020237038678A patent/KR20240007152A/ko active Pending
- 2022-05-10 ES ES22728228T patent/ES3031704T3/es active Active
- 2022-05-10 EP EP25167922.1A patent/EP4609865A3/en active Pending
- 2022-05-10 CR CR20230529A patent/CR20230529A/es unknown
-
2023
- 2023-11-07 CL CL2023003312A patent/CL2023003312A1/es unknown
- 2023-11-10 US US18/506,492 patent/US20240208928A1/en active Pending
- 2023-11-29 CO CONC2023/0016204A patent/CO2023016204A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012907A (es) | 2023-11-08 |
| PL4337652T3 (pl) | 2025-07-14 |
| TW202311245A (zh) | 2023-03-16 |
| SI4337652T1 (sl) | 2025-07-31 |
| RS66893B1 (sr) | 2025-07-31 |
| EP4337652B1 (en) | 2025-04-09 |
| LT4337652T (lt) | 2025-06-25 |
| EP4609865A3 (en) | 2025-10-29 |
| JP2024517917A (ja) | 2024-04-23 |
| DK4337652T3 (da) | 2025-06-10 |
| AR125818A1 (es) | 2023-08-16 |
| BR112023023527A2 (pt) | 2024-01-30 |
| CA3214626A1 (en) | 2022-11-17 |
| AU2022275300A1 (en) | 2023-09-21 |
| MA64323B1 (fr) | 2025-06-30 |
| ES3031704T3 (en) | 2025-07-10 |
| EP4609865A2 (en) | 2025-09-03 |
| PE20240126A1 (es) | 2024-01-22 |
| EP4337652A1 (en) | 2024-03-20 |
| US20240208928A1 (en) | 2024-06-27 |
| FI4337652T3 (fi) | 2025-06-20 |
| HUE071498T2 (hu) | 2025-09-28 |
| WO2022238347A1 (en) | 2022-11-17 |
| HRP20250632T1 (hr) | 2025-07-18 |
| CR20230529A (es) | 2023-12-04 |
| IL307188A (en) | 2023-11-01 |
| CL2023003312A1 (es) | 2024-06-21 |
| CO2023016204A2 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240007152A (ko) | Nlrp3 억제제 | |
| KR20240019083A (ko) | 트리아진 유도체 및 암 치료에서 이의 용도 | |
| TWI850648B (zh) | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 | |
| AU2014358792B2 (en) | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | |
| US20240279237A1 (en) | Fused bicyclic heteroaryl compounds useful as nlrp3 inhibitors | |
| CN118234730A (zh) | 杂环nlrp3抑制剂 | |
| KR20250135228A (ko) | Vav1의 표적 분해 | |
| EA022850B1 (ru) | Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp | |
| TW201107325A (en) | Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof | |
| US20250353830A1 (en) | Novel compounds | |
| US11046686B2 (en) | Thiadiazole IRAK4 compounds | |
| JP2025537238A (ja) | Ｎｌｒｐ３阻害剤としてのトリアジノン誘導体 | |
| JP2020505398A (ja) | 化合物 | |
| US20240043450A1 (en) | New compound | |
| CN117794910A (zh) | Nlrp3抑制剂 | |
| KR20220046593A (ko) | 가교된 헤테로사이클일-치환된 피리미딘 화합물, 이의 제조 방법, 및 이의 약학 용도 | |
| TWI915553B (zh) | 新穎化合物、包含其之組成物以及相關製備方法及醫藥用途 | |
| KR20240165360A (ko) | 에모파밀 결합 단백질 억제제 및 이의 용도 | |
| HK40104195A (zh) | Nlrp3抑制剂 | |
| EA052779B1 (ru) | Триазиновые производные и их применение в лечении рака | |
| NZ619453B2 (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20231109 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250318 Comment text: Request for Examination of Application |